Clinical trials: Melanoma Stage IV
Melanoma
A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients
The purpose of this clinical trial is to find out how successfully, patients with progressive metastatic cutaneous melanoma, are able to develop an immune response to injections with the immunotherapeutic product GSK1572932A when…
- Trial name
- NCT00849875
- Testing
- Immunotherapeutic GSK2132231A, Dacarbazine
- Where
- 14 sites in Belgium, France
- Volunteers
- 48 people
- Sponsor
- GlaxoSmithKline
Metastatic Melanoma
Precision Radiation of Immune Checkpoint Therapy Resistant Melanoma Metastases
To evaluate tumor response, survival and adverse effects after precision radiotherapy (SBRT) in melanoma patients with ongoing PD-1 inhibitor treatment that have tumor progression.
- Trial name
- PROMMEL (NCT04793737)
- Testing
- Precision Radiation (SBRT)
- Where
- Sweden
- Volunteers
- 27 people
- Sponsor
- Karolinska University Hospital
Intraocular Melanoma, Melanoma (Skin)
Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00025181
- Testing
- MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Southern California
Breast Cancer, Kidney Cancer
Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma
RATIONALE: Interferon alfa may interfere with the growth of cancer cells and slow the growth of cancer. PURPOSE: This phase I trial is studying the side effects and best dose of interferon alfa in treating patients with stage IV…
- Conditions
- Breast Cancer, Kidney Cancer, Lymphoma, Melanoma
- Trial name
- IFNa (NCT00276536)
- Testing
- recombinant interferon alpha-1b, IFN
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- The Cleveland Clinic
Melanoma (Skin)
Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from…
- Trial name
- NCT00118313
- Testing
- incomplete Freund's adjuvant, multi-epitope melanoma peptide vaccine, sargramostim
- Where
- United States
- Sponsor
- Craig L Slingluff, Jr
Melanoma and Brain Metastases
Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites
This is a global, multi-centre, open-label, study of GSK2118436 conducted in up to 30 evaluable subjects with resectable, BRAF V600E or V600K mutation-positive metastatic melanoma to the brain.
- Trial name
- NCT01978236
- Testing
- Dabrafenib 150 mg, Trametinib 2.0 mg
- Where
- 3 sites in United States, Australia
- Volunteers
- 6 people
- Sponsor
- GlaxoSmithKline
Clinical Stage III Nodal or Intransit Disease or Resectable Stage IV Melanoma
Early FDG PET in Melanoma
Adult patients with histologically proven melanoma who will be treated with pembrolizumab will undergo FDG PET/CT scan as an early evaluation of response to therapy.
- Trial name
- NCT02716077
- Testing
- FDG PET/CT imaging
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Unresectable Melanoma, Metastatic Melanoma
Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma
The primary purpose of this study is to compare the objective response rate, as determined by investigators, of Nivolumab combined with Ipilimumab versus Ipilimumab monotherapy in patients with untreated, unresectable, or…
- Trial name
- CheckMate 069 (NCT01927419)
- Testing
- Nivolumab, Ipilimumab
- Where
- 21 sites in United States, France
- Volunteers
- 142 people
- Sponsor
- Bristol-Myers Squibb
Melanoma (Skin)
Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as interleukin-2 and interferon alfa stimulate a person's white blood cells to kill…
- Trial name
- NCT00014092
- Testing
- aldesleukin, recombinant interferon alfa, sargramostim
- Where
- 3 sites in United States
- Sponsor
- WVU Medicine Thomas Hospitals
Melanoma (Skin)
Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma
RATIONALE: Inserting a modified herpesvirus gene into a person's melanoma cells may make the cancer more sensitive to the antiviral agent ganciclovir.
- Trial name
- NCT00005057
- Testing
- adenovirus RSV-TK, ganciclovir
- Where
- 3 sites in United States
- Sponsor
- National Human Genome Research Institute (NHGRI)
Melanoma
Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma
Primary Objectives: 1. To determine the maximum tolerated dose (MTD) of intravenous DTIC during the first 2 cycles (6 weeks) of treatment when administered in combination with a fixed dose of oral Lenalidomide in patients with…
- Trial name
- NCT00412581
- Testing
- Lenalidomide, Dacarbazine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Stage III Melanoma, Stage IV Melanoma
Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
The clinical trial is evaluating a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on melanoma
- Trial name
- NCT01026051
- Testing
- MKC1106-MT
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Mannkind Corporation
Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
This phase Ib trial studies the side effects and best dose of selinexor when given together with several different standard chemotherapy or immunotherapy regimens in treating patients with malignancies that have spread to other…
- Conditions
- Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Fallopian Tube Carcinoma
- Trial name
- NCT02419495
- Testing
- Capecitabine, Carboplatin, Cyclophosphamide
- Where
- 5 sites in United States
- Volunteers
- 221 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma Stage Iv, Melanoma Metastatic
Surgery for Gastrointestinal Metastases of Malignant Melanoma - a Single Center Retrospective Cohort Study
The aim is to conduct a single centre retrospective study of all patients with stage IV melanoma that underwent surgery for metastases at Sahlgrenska University Hospital between 2010-01-01 and 2018-12-31.
- Conditions
- Melanoma Stage Iv, Melanoma Metastatic, Abdominal Tumor
- Trial name
- SurgMelMet (NCT03879395)
- Testing
- Abdominal surgery with metastasectomy
- Where
- Sweden
- Volunteers
- 15 people
- Sponsor
- Vastra Gotaland Region
Metastatic Melanoma
IL-17 Blockade to Decrease irAEs (REPLAY)
The primary objective of this study is to determine the safety and feasibility of administering an IL-17A (human IgG1κ) monoclonal antibody, (Secukinumab, Cosentyx®) to participants with metastatic melanoma who have previously…
- Trial name
- REPLAY (NCT07237594)
- Testing
- Secukinumab Injection
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Duke University
Metastatic Melanoma, Locally Advanced Refractory/Recurrent Melanoma
Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors
To determine whether special tumor fighting cells that is taken from participants' tumors and grown in the laboratory and then given back to the participant will fight the participant's cancer when their immune system is…
- Conditions
- Metastatic Melanoma, Locally Advanced Refractory/Recurrent Melanoma, Metastatic Head and Neck Cancer, Locally Advanced Refractory/Recurrent Head and Neck Cancer
- Trial name
- NCT03991741
- Testing
- Autologous Tumor Infiltrating Lymphocytes, High-Dose Interleukin 2
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Gregory Daniels
Clinical Stage III Cutaneous Melanoma AJCC V8, Clinical Stage IV Cutaneous Melanoma AJCC V8
Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma
This phase II trial studies how well binimetinib and nivolumab work in treating patients with BRAF V600 wildtype melanoma that has spread to nearby tissues or lymph nodes and cannot be removed by surgery (locally advanced…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC V8, Clinical Stage IV Cutaneous Melanoma AJCC V8, Locally Advanced Cutaneous Melanoma, Metastatic Cutaneous Melanoma
- Trial name
- NCT04375527
- Testing
- Binimetinib, Nivolumab, Questionnaire Administration
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Stage IV Melanoma
A Study of Volociximab in Metastatic Melanoma
This is a Phase 2, multicenter, research study determining the effects of an investigational drug called volociximab in metastatic melanoma. The purpose of the study is to compare the clinical benefit and safety of volociximab.
- Trial name
- NCT00369395
- Testing
- volociximab
- Where
- 7 sites in United States
- Volunteers
- 19 people
- Sponsor
- Abbott
Metastatic Melanoma to the Groin Lymph Nodes
Evaluation of Groin Lymphadenectomy Extent For Metastatic Melanoma
BACKGROUND: Spread of metastatic melanoma to the groin lymph nodes (LN) is a common event affecting about 350 people a year in Australia.
- Trial name
- EAGLE FM (NCT02166788)
- Testing
- Inguinal Lymphadenectomy, Ilio-inguinal Lymphadenectomy
- Where
- 17 sites in Australia, Brazil and 4 more
- Volunteers
- 634 people
- Sponsor
- Melanoma and Skin Cancer Trials Limited
Metastatic Melanoma
Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma
This is an open label, two-phase study combining a dose escalation Phase 1 with a proof-of-concept Phase 2 in patients with unresectable or metastatic melanoma, for whom treatment with ipilimumab is indicated.
- Trial name
- NCT01689870
- Testing
- Anti-OX40, Ipilimumab
- Sponsor
- Ludwig Institute for Cancer Research
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.